Document is current

Article History

Received: 5 August 2025

Accepted: 17 September 2025

First Online: 11 October 2025

Declarations

:

: Kelsey Uminski has received educational grants from CSL Behring, Roche and Novo Nordisk, research funding from Bayer and Novo Nordisk, consultancy fees from Bayer, Biocryst Pharmaceuticals, Novo Nordisk, Roche, Sanofi and Takeda, speaker fees from Bayer, CSL Behring, Pfizer, Roche, Sanofi, and Takeda, and travel support from Novo Nordisk, Octapharma, Roche,and Sanofi. Dawn Goodyear reports advisory boards and consultancy from Alexion, BioCryst, CSL Behring, Medison, Pfizer, Octapharma, Sanofi, Sobi, Roche and Takeda; research funding from Takeda. Stephen Betschel has participated in advisory board or equivalent for Astria, Biocryst Pharmaceuticals, CSL Behring, Ionis, Kalvista, Pharvaris, Sanofi and Takeda, received grants or honoraria from Biocryst Pharmaceuticals, CSL Behring, Kalvista and Takeda, and participating or participated in a clinical trial with Takeda.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.